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ABSTRACT
A cooperative effort between the NASA/Johnson Space Center (JSC) and the Baylor College of Medicine
(BCM) has been underway since 1988 to develop a long-term implantable Ventricular Assist Device (VAD).
VAD is intended to boost the cardiac output of patients with deteriorated cardiac function. For many of these
patients, the best alternative is heart transplantation. Heart transplantation is a complex and expensive procedure
and usually requires a long waiting period for a donor heart. The condition of the patient often deteriorates during
this waiting period which complicates the pie and post-operative care. Because of these factors, the need for a long-
term implantable VAD for use as a bridge-to-transplant device or as a permanent assist device has become the focus
of much research. The need for a VAD has been estimated at 50,000 to 60,000 patients per year in the United
Slates alone[l]. A device which satisfies all the system performance and reliability requirements has yet to be
achieved. However, the development of the NASA/Baylor VAD has progressed to state in which commercial
viability can begin to be considered. The device is small, simple, efficient and reliable which meets all
requirements for a tOtally implantable VAD.
HISTORY OF VAD'S
The first widely successful device used tO pump blood was invented over fifty years ago by Dr. Michael
DcBakey. This pump was called the roller pump and utilized flexible tubing squeezed by rollers to propel the
blood. This type of pump is still used today during open heart surgery; however, advances with other types of
pumps is rendering the roller pump obsolete. During the 1960 - 1980 time period, much work was focused on the
development of a Total Artificial Heart (TAH). This work was culminated by the implantation of the Jarvik-7
TAll in six patients[2] during the 1980's, but with limited success. Attention has recently shifted toward the
development of a VAD rather than a TAH for several reasons. A VAD operates in parallel with the natural heart by
drawing blood from the ventricle (usually the left) and discharging into the descending aorta as shown in Figure 1.
Typically, VAD's are utilized in patients unable tO be weaned from heart bypass systems after open heart surgery.
Weaning is necessary after cardiac surgery when the natural heart is unable to sustain life. This application of a
VAD is generally short term (up tO one week); however, some cardiac patients could benefit from a permanently
implanted device. For those patients who cannot be weaned from the temporary artificial assist system, a
permanent implantable VAD can be used negating the need for a total wansplant, artificial or biological. For these
reasons several types of VAD's have recently been developed to fulfill a variety of medical needs.
Many of these second generation pumps are cena'ifugal designs which have been modified to meet the needs
for providing circulatory assist. They are much smaller and more efficient than the original roller pump, but are
restricted to cxtracorporeal pulmonary and systemic circulatory assist. The need for an implantable device led the
NASA/Baylor team to pursue an axial flow design which has resulted in a VAD which is small enough to fit inside
small children. The two main obstacles which had to be overcome were hemolysis and thrombosis. Hemolysis is
the mechanical and chemical destruction of red blood cells resulting in the release of hemoglobin into the blood
plasma. This causes two problems, the first being a reduction in the oxygen ca,Tying capability of the blood and
the second is toxicity due to excess levels of hemoglobin in the plasma. The kidneys and liver can remove small
amounLs of hemoglobin from the bloodstream through filtration and metabolic absorption, respectively. If the
destruction of red blood cells exceeds a threshold, then hemolytic anemia and hemoglobin toxicity begin to occur.
Thrombosis is the formation of blood clots within the pump which can cause pump seizure, increased hemolysis,
or blockage of the circulatory system itself. Blood tends to clot when contact is made with any foreign substance
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within the bloodstream. Other causes of thrombosis are stagnant areas in which blood is allowed to collect and
coagulate and platelet damage which causes the release of platelet factors. "I'nesc factors initiate the coagulation
cascade which results in an ag$regate of fibrin, platelets, erythrocytes, etc. These blood components can adhere to
pmnp surfaces and cause the pump to seize. Coatings can to some extent reduce thrombosis, but the basic design
of the pump must be antithrombogenic if the device is expected to last long periods of time within the circulatory
system. Both the roller pump and second generation centrifugal pumps are limited to a pump life of less than two
days for these and other reasons. Pulsatile VAD's using flexible diaphragms have demonstrated much longer pump
life, but have yet to be reduced to a size which would allow implantation in a wide range of patients. In addition,
pulsatile VAD's have proven to be very expensive and complex to produce prohibiting their use on a wide basis.
DESIGN REQUIREMENTS
The design requirements for the NASA/Baylor VAD were based on years of practical medical experience as well
as the demanding environment inside the circulatory system. The basic requirements of low hemolysis and
antithrombogenicity were of primary concern. However, careful attention to minimizing size and maximizing
efficiency have resulted in a device which has the potential to satisfy wide ranging circulatory assist needs. As with
any device which will be put to use in an environment with limited access, the importance of system and
component reliability could not be overemphasized. This drove the design towards simplicity with a minimum
number of components, both electrical and mechanical. Output was required to be 5.0 liters/minute against a
pressure head of 100 nun-Hg. This was based on the required assist flow during previous clinical usage of
temporary VAD systems. A power input of less than 10 watts was highly desirable to minimize the size of the
battery pack and the frequency of recharging. After evaluation of these requirements, it was decided that a small,
efficient, axial flow pump was most likely to fulfill all the criteria while maintaining a relatively low production
cost.
PUMP DESIGN
The NASA/Baylor VAD is shown in Figure 2. The envelope dimensions of the device are 2.5 inches (7.0 can)
in length and 1.0 inch (2.5 cm) in diameter. The unit consists of a spinning inducer/impeller with a fixed flow
straightener and diffuser which reside inside of a flow tube. The inducer/impeller is 0.46 inches (1.2 can) in
diameter and is designed to rotate between 10,000 to 15,000 RPM depending upon the required pump output. The
inducer serves two roles, one is to pre-rotate the blood before entering the impeller section and the other is to
provide a two-stage pumping effect. The impeller also serves a dual purpose by housing rare earth magnets in the
blades to act as a rotor of a brushless De motor as well as providing pumping action. Magnets implanted in the
impeller blades allows for a small air gap which results in a high motor efficiency. The inducer and impeller
perform together to provide an efficient pumping mechanism to propel the blood while maintaining low shear
levels and minimizing strong vortices. As a result, hemolysis is kept at an acceptable level for permanent human
use. The blood flow is axially directed by the flow straightener before entering the inducer to boost performance.
The flow straightener also provides a support for the front bearing. The diffuser axially redirects the highly
tangential flow leaving the impeller to build pressure for increased pump performance and also minimizes
turbulence to reduce hemolysis levels. The diffuser also serves as a support for the rear bearing. The front bearing
consists of a ceramic ball riding in a matching sapphire cup. This simple bearing design accommodates both radial
and axial forces encountered during pump operation. The rear bearing, equally simple, consists of a ceramic shaft
riding inside a sapphire sleeve. _ clearance between the shaft and the sleeve is kept very small to ensure precise
alignment and minimize blood leakage into the bearing. The small amount of blood which does initially enter the
bearing area is cross-linked by localized heat and effectively fills all the bearing voids. This prevents a constant
infusion of fresh blood which could cause the bearing to seize. A brushless DC motor winding is located outside
the flow tube and placed over the impeller to provide a magnetic drive for the inducer/impeller. The pump
components (inducer/impeller, flow straightener, and diffuser) are currently machined from polycarbonate, but other
materials are being investigated in terms of both biocompatibility and mass production issues.
CONTROLLER AND POWER SYSTEM DESIGN
Minimizing the size of the controller was a major design goal since it also is intended for implantation A
brushless DC motor drive was chosen due to its simplicity, reliability and high efficiency. Commercially available
controllers are relatively complex requiring multiple components and sensors, all of which are potential failure
points. Among these are Hall effect sensors used to detect rotor position. These signals are used to commutate the
motor. A control scheme was adopted for the NASA/Baylor VAD which is shown in Figure 3. This scheme
eliminated Hall effect sensors and the related electronics by relying on the back-electromotive force (back EMF)
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generated in the motor stator. The back.EMF sign,s can be used to detect the rotor position and enable optimum
commutation of the motor. This control method not only reduced the number of electronic components to a
minimum, but also was slightly more efficient than standard Hall effect sensor controller,. The power deriveD,
system, borrowed from existing technology with little modification, is called the Trauscutaneous Energy Transfer
System ('lETS). This system was developed for pulsatUe VAD's and has proven to be safe, reliable, and efficient.
it uses AC coupling to transfer power through the skin eliminating possible infection sites.
SYSTEM PERFORMANCE
Hydraulic and _ec--Ir_m
Hydraulic performance of the device is shown in Figure 4. The RPM required for 5.0 liter_min against 100
mm-Hg is relatively low at 10,800 for a device of this size. These flow curves were obtained using a mixture of
37% glycerin and 63% water. This mixture produces a fluid viscosity and density similar to that of human blood.
The pump is capable of producing much higher flows and pressures as can be seen in Figure 4. This capability
allows the pump to supply sufficient flows for a wide variety of patients depending upon their cardiac output and
mean arterial pressure. It also enables the pump to be used in applications which involve the use of an oxygenatof
for pulmonary assist such as Extracorporeal Membrane Oxygenation (ECMO). The hydraulic efficiency of the
pump has been estimated at 33% using the glycerin/water mixture. This coupled with a high motor efficiency
allows the pump to draw only 9 watts of power to produce the required flow and pressure. A new motor design
which is currently under development is expected to reduce this power requirement to between 5 and 6 watts.
Hemolysis and Thrombosi._
The hemolytic nature of a pump is characterized by the level of hemoglobin in the blood plasma. Evaluation
of hemolysis in vivo is impractical due to the fact that the kidneys and liver remove or metabolically absorb
hemoglobin to varying degrees depending upon organ function, if a pump is run with blood in vitro, the amount
of liberated hemoglobin can be precisely determined by measuring plasma free hemoglobin levels at specific time
intervals. In 1967, Koller [3] established an Index of Hemolysis (Ill) to specify an acceptable level of hemolysis
for human use and to facilitate comparison of different pumps under development. A normalized Index of
Hemolysis (N.I.H.) [4,5] was established to compensate for differen! hematocrit levels found in different tests. It isdefined as:
N.I.H= AHgb x V x (I-Hi) x I00 1(Q x I") (I)
where, AHgb = change in plasma free hemoglobin in grams pe_ liter
V = blood volume offluidcircuitinliters
Ht = hematocritofblood indecimalpercent
Q = bloodflow rateinliters/minute
T = time in minutes atspecif'w._dflow rate
The N.I.H. is measured as grams per 100 liters and is defined as the grams of hemoglobin liberated by a pump
which passes 100 liters of blood against a standard pressure of 100 mm Hg. An acceptable value of IH for
permanenthuman use has beenestablished at less than0.06 8/100L. This value is characteristicof the performance
of the original roller pump. The IH of the NASA/Baylor pump has been determined to be 0.018 g/100L using
bovine blood. An increase of roughly three times is typical when transitioning from bovine to human blood due to
an increase in the fragility. This would place the IH of the NASA/Baylor pump at 0.042 8/100L with human
blood. Testing with human blood in the near future will likely conf'u-m this extrapolation. In vivo experiments
with calf models have shown that the pump produced no hemolysis problems. Further reductions in hemolysis are
expected as the surface finish of the pump components is improved by a combination of mechanical and chemical
polishing. Mass production parts are likely to be injection molded which will produce a superior surface finish.
Thrombosis can be evaluated in vivo. Blood clotting involves _. complex cascade of chemical reactions which
has not yet been duplicated in vitro. For this reason, initial animal studies have been conducted to evaluate
thrombus formation with the NASA/Baylor VAD. Two calf implants have been conducted to date in which the
pump was implanted paracorporeally. The first experiment was terminated after 36 hours due to excessive
hemolysis caused by improper sealing of the magnets in the impeller blades resulting in rapid magnet corrosion.
The magnet sealing problem was solved for the second implant. The second experiment lasted 4.5 days before
termination. No hemolysis problems were observed and the pump provided more than sufficient flow while
drawing 11 watts of power. The increased power required was due to the added resistance of the tubing used to
implant the pump paracorporeaJly. This resulted in an increased RPM requirement which in turn required slightly
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more power than expected. "Ibis increased power would not be requited wizen the pump is implanted close to the
beret. The animal tolerated the pump well With no adverse effects. The pump stopped after 4.5 dayl due to
_mmbus formation mound the rear beaxlng. A redesigned reK bemlng Ires been developed widch wUl llkelY mlve
this problem. In addidon some thromlms formation was noted on the leading edges of tie inducer blades. Upon
exnminati_ under a m/croscope, it was determined that this m'ea _ a very POOr surface finish. It is expe_
that improvements in surface finish will not only reduce hemolysis, but also reduce if not eliminate thromlxts
formation on the leading edges of the inducer blades.
CONCLUSION
A small, implantable, and efficient VAD has been developed by the NASA/Baylor team. 'I'nis system has a great
potential for satisfying the requirements for a long-term VAD for use as a _idge.to-transplant or permanent assist
device. The technology has been developed sufficiently to begin to consider commercial application. _ potential
market for an implantable VAD has been estimated to be substantial and will grow at a rapid pace once a safe,
reliable, and cost-effective system is available. The potential benefit to mankind is equally great given the global
shortage of donor hearts and the reality that a commercially viable TAH will probably not be achieved in
immediate future.
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